D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
CAMBRIDGE, MA—Michael Halpin, Chief Operating Officer of Vericel Corp (NASDAQ:VCEL), recently executed significant transactions involving the company’s common stock. According to a recent SEC filing, Halpin sold 10,000 shares at a price of $49.52 per share, resulting in a total sale value of $495,200. The transaction comes as Vericel, currently valued at $2.58 billion, trades near $51.53 per share, with the stock showing significant volatility this year, down 6.87% year-to-date.
Additionally, Halpin exercised stock options to acquire 10,000 shares at $16.66 per share, a move that was part of a broader set of transactions. The option exercise was valued at $166,600. These actions were conducted under an automatic sale plan pursuant to Rule 10b5-1, which Halpin adopted in November 2024. According to InvestingPro, which offers comprehensive analysis of 1,400+ stocks including Vericel, the company currently trades at a P/E ratio of 241.46, suggesting a premium valuation relative to peers.
After these transactions, Halpin holds 15,539 shares directly. The sales and acquisitions were part of routine portfolio management and align with Halpin’s ongoing service to the company. The stock has demonstrated resilience, trading within a 52-week range of $39.12 to $63.00, with multiple additional insights available through InvestingPro’s detailed research reports.
In other recent news, Vericel Corporation reported strong financial results for the fourth quarter of 2024, with a 20% year-over-year revenue increase to $237.2 million and a net income of $10.4 million, marking a significant improvement from a loss in the previous year. The company achieved a record gross margin of 78% in Q4 and provided optimistic guidance for 2025, projecting revenue growth of 20-23%. Truist Securities adjusted its price target for Vericel to $61 from $67, while maintaining a Buy rating, highlighting the potential for growth with the launch of new products like MACI Arthro and Nexobrid. Despite a shortfall in Epicel revenue, the performance of MACI, a cartilage repair product, showed accelerated growth, contributing positively to the company’s financial outlook. Analysts at Truist suggested that Vericel’s guidance might be conservative, considering the anticipated impact of new product launches. The company has also seen a positive market reaction, with strong investor confidence reflected in its stock performance. Vericel’s strategic initiatives, including product launches and market expansions, are expected to drive future growth, with the company positioning itself for sustained high revenue and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.